ArticleNature medicine2025

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.

Jia Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.